GH Research (GHRS) Cash & Current Investments (2020 - 2025)
GH Research (GHRS) recorded quarterly Cash & Current Investments of $100.8 million in Q4 2025, little changed quarter-over-quarter from $100.8 million in Q3 2025, and down 16.13% on a YoY basis from $120.2 million in Q4 2024.
GH Research (GHRS) Cash & Current Investments (2020 - 2025) Analysis & Trends
GH Research's Cash & Current Investments history runs 6 years deep, the most recent figure standing at $100.8 million for Q4 2025.
- In Q4 2025, Cash & Current Investments fell 16.13% year-over-year to $100.8 million; the TTM figure through Dec 2025 stood at $100.8 million (down 16.13% YoY), while the FY2025 annual figure was $100.8 million, down 16.13% from the prior year.
- Cash & Current Investments was $100.8 million for Q4 2025 at GH Research, roughly flat from $100.8 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $280.7 million in Q3 2021 to a low of $5.9 million in Q1 2021.
- Historically, Cash & Current Investments has averaged $163.3 million across 5 years, with a median of $131.6 million in 2023.
- The sharpest annual moves came in 2021 and 2024: Cash & Current Investments surged 5535620.0% in 2021, then slumped 44.65% in 2024.
- A 5-year view of Cash & Current Investments shows it stood at $276.8 million in 2021, then plunged by 40.04% to $166.0 million in 2022, then slipped by 19.23% to $134.0 million in 2023, then dropped by 10.34% to $120.2 million in 2024, then decreased by 16.13% to $100.8 million in 2025.
- The last three Cash & Current Investments figures came in at $100.8 million (Q4 2025), $100.8 million (Q3 2025), and $100.8 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | 32.30 Mn |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 2.13 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 286.70 Mn |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 2.77 Mn |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | 18.44 Mn |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 7.25 Bn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | GH Research | 9.73 Bn | 9.63 Bn | - | 100.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 100.79 Mn |
| Sep 30, 2025 | 100.79 Mn |
| Jun 30, 2025 | 100.79 Mn |
| Mar 31, 2025 | 113.35 Mn |
| Dec 31, 2024 | 120.18 Mn |
| Sep 30, 2024 | 122.58 Mn |
| Jun 30, 2024 | 129.10 Mn |
| Mar 31, 2024 | 128.83 Mn |
| Dec 31, 2023 | 134.04 Mn |
| Sep 30, 2023 | 221.45 Mn |
| Jun 30, 2023 | 220.68 Mn |
| Mar 31, 2023 | 220.01 Mn |
| Dec 31, 2022 | 165.96 Mn |
| Sep 30, 2022 | 276.78 Mn |
| Jun 30, 2022 | 265.38 Mn |
| Mar 31, 2022 | 276.78 Mn |
| Dec 31, 2021 | 276.79 Mn |
| Sep 30, 2021 | 280.75 Mn |
| Jun 30, 2021 | 5.90 Mn |
| Mar 31, 2021 | 5.90 Mn |